Search

Your search keyword '"Lebbe C"' showing total 1,160 results

Search Constraints

Start Over You searched for: Author "Lebbe C" Remove constraint Author: "Lebbe C"
1,160 results on '"Lebbe C"'

Search Results

1. Long-term outcomes among patients who respond within the first year to nivolumab plus ipilimumab or nivolumab monotherapy: A pooled analysis in 935 patients

2. Cutaneous melanoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

7. Improved nationwide survival of sarcoma patients with a network of reference centers

9. Sclerosing Epithelioid Fibrosarcoma (SEF) versus Low Grade Fibromyxoid Sarcoma (LGFMS): Presentation and outcome in the nationwide NETSARC+ series of 330 patients over 13 years

11. Epithelioid hemangio-endothelioma (EHE) in NETSARC: The nationwide series of 267 patients over 12 years

12. Single-agent anti-PD-1 or combined with ipilimumab in patients with mucosal melanoma: an international, retrospective, cohort study

16. Delayed immune-related adverse events with anti-PD-1-based immunotherapy in melanoma

17. Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study

19. Relevance of body mass index as a predictor of systemic therapy outcomes in metastatic melanoma: analysis of the MelBase French cohort data☆

21. ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO Guidelines Committee

22. ESMO consensus conference recommendations on the management of locoregional melanoma: under the auspices of the ESMO Guidelines Committee

26. Update of survival and cost of metastatic melanoma with new drugs: Estimations from the MelBase cohort

27. Access to innovative medicines for metastatic melanoma worldwide: Melanoma World Society and European Association of Dermato-oncology survey in 34 countries

29. Sclerosing Epithelioid Fibrosarcoma (SEF) versus Low Grade Fibromyxoid Sarcoma (LGFMS): presentation and outcome in the nationwide NETSARC+ series of 330 patients over 13 years

31. Improved survival using specialized multidisciplinary board in sarcoma patients

32. More than 5000 patients with metastatic melanoma in Europe per year do not have access to recommended first-line innovative treatments

35. The combination of ipilimumab and nivolumab is still not reimbursed for BRAF-mutated melanoma patients in France: An unacceptable medical situation that raises ethical concerns

40. A-308 - A phase 3 study of the efficacy, safety, and pharmacokinetics profile of subcutaneous vs intravenous nivolumab + relatlimab fixed-dose combination in previously untreated metastatic or unresectable melanoma (RELATIVITY-127)

44. Cutaneous manifestations induced by check point inhibitors in 120 melanoma patients—The European MelSkinTox study

Catalog

Books, media, physical & digital resources